StemSynergy Therapeutics®
"Innovative Stem Cell Research. Targeted Cancer Therapeutics."

Scientific Team

The SSTI team has extensive working experience in the biotech/pharmaceutical industry.  Our team has broad experience in medicinal chemistry, drug development and cancer biology to progress our programs into the clinical stages and beyond.

Darren Orton, Ph.D.

Dr. Darren Orton is the Director of Medicinal Chemistry at SSTI. He has over 20 years of experience in all phases of drug discovery and development. Prior to joining SSTI, he was at Vanderbilt University, where he specialized in early lead discovery, high-throughput screening and molecular modeling. At Albany Molecular Research, he was part of a team that collaborated with Bristol-Myers Squibb to take BMS708163 (a Gamma-Secretase inhibitor) into clinical trials. Dr. Orton received his Ph.D. degree at the University of Durham in organic chemistry, working on the synthesis of natural products. He completed an industrial placement year in medicinal chemistry at Sanofi in the United Kingdom.

Thomas Doundoulakis, Ph.D.

Dr. Thomas Doundoulakis is a Senior Principal Scientist at SSTI. His experience in medicinal chemistry includes all phases of preclinical drug development. Prior to joining SSTI, he worked at Sirrus Chemistry (formerly Bioformix). Dr. Doundoulakis received his Ph.D. degree from the University of Texas at Arlington in organic chemistry, exploring synthetic studies towards palau’amine and linker modified derivatives of bioactive molecules.

Dennis Fei, Ph.D.

Dr. Dennis Fei is a Senior Principal Scientist at SSTI. His research focused on elucidating the functions of novel oncogenes and how developmental pathways contribute to cancer. Dr. Fei received his Ph.D. degree in Pharmacology and Toxicology at Dartmouth College, and completed his postdoctoral training at National Human Genome Research Institute and Weill Cornell Medicine.

Will Guerrant, Ph.D.

Dr. Will Guerrant is a Senior Principal Scientist at SSTI. His research focused on identifying targetable oncogenic biology within the Hippo-YAP pathway as potential new therapeutics for many cancers. Dr. Guerrant has more than ten years’ experience with drug discovery and preclinical development. He received his Ph.D. degree in Chemistry and Biochemistry from the Georgia Institute of Technology, and completed his postdoctoral training at The Scripps Research Institute.

Matthew Knowe, Ph.D.

Dr. Matthew Knowe is a Principal Scientist at SSTI. He developed a novel organocatalyst for the enantioselective desymmetrization of carboxylic acids, and applied these methods towards improved synthesis of biologically relevant small molecules. He also prepared isotopically labeled sterols for use as internal standards in mass spectrometry to assay sterol stasis and metabolism. Dr. Knowe received his Ph.D. degree in Chemistry from Vanderbilt University in the areas of synthetic methodology, catalysis, and total synthesis, and completed his postdoctoral training at Vanderbilt University.

Michael Beauzieux, M.S.

Michael Beauzieux is a Scientist at SSTI. His research focused on developing novel chemoresistant leukemia cell models. Michael received his master’s degree in Biochemistry and Molecular Biology from University of Miami.

Scientific Team

SSTI has a multidisciplinary team of scientists.

Meet the Team


Meet the founders behind StemSynergy Therapeutics, Inc.



SSTI targets cancer stem cell pathways that drive tumor growth.

Scientific Programs